Novel CD20 monoclonal antibodies for lymphoma therapy
1 Department of Oncology, People’s Hospital, Henan Province, China
2 Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY, 10595, USA
Journal of Hematology & Oncology 2012, 5:64 doi:10.1186/1756-8722-5-64Published: 11 October 2012
Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-cell lymphoma. However, suboptimal response and /or resistance to rituximab have remained a challenge in the therapy of B-cell non-Hodgkin’s lymphoma (NHL). Novel agents are under active clinical trials. This review will summarize the latest development in new mAbs against CD20, which include second-generation mAbs, ofatumumab, veltuzumab (IMMU-106), ocrelizumab (PRO70769), and third-generation mAbs, AME-133v (ocaratuzumab), PRO131921 and GA101 (obinutumumab).